Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that the combination of docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective alone or as a backbone regimen for newly developed targeted agents for the treatment of patients with advanced gastric cancer.
For this phase 2 study, researchers sought to evaluate docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/capecitabine (TEX), and TEF in patients with metastatic or locally recurrent gastric adenocarcinoma. Researchers randomly assigned 248 patients with advanced gastric cancer 1:1:1 to TE, TEF, or TEX.
Results showed a median progression survival of 7.66 months (95% CI: 6.97 - 9.40) for TEF, 4.50 months (95% CI: 3.68 - 5.32) for TE, and 5.55 months (95% CI: 4.30 - 6.37) for TEX. Median overall survival was 14.59 months (95% CI: 11.70 - 21.78) for TEF, 8.97 months (95% CI: 7.79 - 10.87) for TE, and 11.30 months (95% CI: 8.08 - 14.03) for TEX.
Tumor response rate for TEF was nearly double that of TE and TEX. Adverse effects were similar across all arms. The researchers suggest that TEF should be studied in phase 3 trials for patients with advanced gastric cancer alone or with targeted therapy.
Docetaxel, oxaliplatin, and TEF may be effective for the treatment of patients with advanced gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer
- No Benefit Seen From HSCT in Hypodiploid B-ALL
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol